Status:
UNKNOWN
miRNA and Relevant Biomarkers of BC Patients Undergoing Neoadjuvant Treatment
Lead Sponsor:
Cui Yimin
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-75 years
Brief Summary
MicroRNA (miRNA) is a type of endogenous non-coding RNA. They are responsible for post-transcriptional regulation and participate in many vital biological processes. Expression profiling has shown tha...
Detailed Description
Current reports showed that serum microRNA expression could be used as an early marker for determining the breast cancer risk. The concentrations of some circulating microRNAs in human breast cancer h...
Eligibility Criteria
Inclusion
- Early breast cancer patients;
- Stage II-III disease;
- sign informed consent form;
- receive neoadjuvant treatment;
- Age between 18-75.
Exclusion
- Women during pregnancy;
- Metastasis patients or stage IV breast cancer patients;
- Male breast cancer patients;
- Inflammatory breast cancer patients;
- Patients with neoadjuvant endocrine treatment.
Key Trial Info
Start Date :
November 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03779022
Start Date
November 1 2015
End Date
December 31 2019
Last Update
August 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034